PROS1 and benign prostatic hyperplasia: Giskeødegård and colleagues [96] provide a potential basis for the observed alterations in PC seen in metastatic patients in our study, and they provide further support for phylometabolomic analysis as an enhanced method to distinguish PCa from BPH than PSA.